Publications (2012)
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D’Sa S, Rabin N, Johnston R, Schey S, Yong K
Br J Haematology (in press) (2012)
First-line erlotinib in patients with advanced non-small cell lung cancer unsuitable for chemotherapy: a double-blind, placebo controlled, phase III trial (TOPICAL)
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C
Lancet Oncology (in press) (2012)
Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
Jitlal M, Khan I, Lee SM, Hackshaw A
Br J Cancer (in press) (2012)
Exploiting FOXM1-Orchestrated Molecular Network for Early Squamous Cell Carcinoma Diagnosis and Prognosis
Teh MT, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Purdie K, Harwood C, Wan H, Odell EW, Hackshaw A, Waseem A
Int J Cancer (in press) (2012)
Post-ASCT consolidation with low dose thalidomide, cyclophosphamide and dexamethasone is well tolerated and improves depth of response in patients undergoing high dose therapy as part of upfront treatment for multiple myeloma
N Rabin, L Percy, I Khan, J Quinn, S D’Sa, K Yong
Br J Haematol. 2012 Jun 19. doi: 10.1111/j.1365-2141.2012.09188.x. [Epub ahead of print] (2012)
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T
J Hepatol. 2011 Dec; 55(6):1309-16. (2012)
Attitudes to participation in a lung cancer screening trial: a qualitative study
Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro S, Griffiths C
Thorax 2012; 67:5 418-425 (2012)
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A
N Engl J Med. 2012;366(18):1674-85 (2012)
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U
N Engl J Med. 2012 Apr 12;366(15):1382-92. (2012)
Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
Hardwick N, Ledermann JA, Aitkens E, Chain B
Cancer Immunol Immunother. 2012 Apr 5. [Epub ahead of print] (2012)
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B; for the EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG)
Ann Oncol. 2012 Mar 19. [Epub ahead of print] (2012)
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery
Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA
Int J Gynecol Cancer. 2012 May;22(4):566-72 (2012)
Family history and women with ovarian cancer: is it asked and does it matter?: An observational study
Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L
Int J Gynecol Cancer. 2012 Feb;22(2):254-9. (2012)
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ
Br J Cancer. 2012 Mar 13;106(6):1153-9 (2012)
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial.
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P
Radiother Oncol. 2011 Jul;100(1):86-92. Epub 2011 Jun 12. (2012)
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C
Lancet. Nov 2012; 13:11: 1161-1170. (2012)
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
Raja FA, Hook JM, Ledermann JA
Cancer Treat Rev. (2012)
